ELEM is a pioneer in biomedical simulation technology, creating virtual human populations for drug & device safety assessment. Its expertise lies in biomedical engineering, biophysical modelling & supercomputing replicating organ function, with an initial focus on cardiovascular disease. Medical trial failures plague drug development, with cardiac safety issues a major concern. ELEM's platform enables supercomputer-based trials to assess drug safety, supporting drug repurposing and accelerating regulatory approval. Its virtual humans provide evidence for decision-making, pipeline optimisation, risk reduction and cost avoidance for pharmaceutical companies, CROs and device manufacturers.